Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;25(2):520-527.
doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.

A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group

Caroline E Poorman  1 , Cecilia G Ethun  1 , Lauren M Postlewait  1 , Thuy B Tran  2 , Jason D Prescott  3 , Timothy M Pawlik  3 , Tracy S Wang  4 , Jason Glenn  4 , Ioannis Hatzaras  5 , Rivfka Shenoy  5 , John E Phay  6 , Kara Keplinger  6 , Ryan C Fields  7 , Linda X Jin  7 , Sharon M Weber  8 , Ahmed Salem  8 , Jason K Sicklick  9 , Shady Gad  9 , Adam C Yopp  10 , John C Mansour  10 , Quan-Yang Duh  11 , Natalie Seiser  11 , Carmen C Solórzano  12 , Colleen M Kiernan  12 , Konstantinos I Votanopoulos  13 , Edward A Levine  13 , Charles A Staley  1 , George A Poultsides  2 , Shishir K Maithel  14   15
Affiliations

A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group

Caroline E Poorman et al. Ann Surg Oncol. 2018 Feb.

Abstract

Background: The 7th AJCC T-stage system for adrenocortical carcinoma (ACC), based on size and extra-adrenal invasion, does not adequately stratify patients by survival. Lymphovascular invasion (LVI) is a known poor prognostic factor. We propose a novel T-stage system that incorporates LVI to better risk-stratify patients undergoing resection for ACC.

Method: Patients undergoing curative-intent resections for ACC from 1993 to 2014 at 13 institutions comprising the US ACC Group were included. Primary outcome was disease-specific survival (DSS).

Results: Of the 265 patients with ACC, 149 were included for analysis. The current T-stage system failed to differentiate patients with T2 versus T3 disease (p = 0.10). Presence of LVI was associated with worse DSS versus no LVI (36 mo vs. 168 mo; p = 0.001). After accounting for the individual components of the current T-stage system (size, extra-adrenal invasion), LVI remained a poor prognostic factor on multivariable analysis (hazard ratio 2.14, 95% confidence interval 1.05-4.38, p = 0.04). LVI positivity further stratified patients with T2 and T3 disease (T2: 37 mo vs. median not reached; T3: 36 mo vs. 96 mo; p = 0.03) but did not influence survival in patients with T1 or T4 disease. By incorporating LVI, a new T-stage classification system was created: [T1: ≤ 5 cm, (-)local invasion, (+/-)LVI; T2: > 5 cm, (-)local invasion, (-)LVI OR any size, (+)local invasion, (-)LVI; T3: > 5 cm, (-)local invasion, (+)LVI OR any size, (+)local invasion, (+)LVI; T4: any size, (+)adjacent organ invasion, (+/-)LVI]. Each progressive new T-stage group was associated with worse median DSS (T1: 167 mo; T2: 96 mo; T3: 37 mo; T4: 15 mo; p < 0.001).

Conclusions: Compared with the current T-stage system, the proposed T-stage system, which incorporates LVI, better differentiates T2 and T3 disease and accurately stratifies patients by disease-specific survival. If externally validated, this T-stage classification should be considered for future AJCC staging systems.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
AJCC 7th/8th edition and proposed T-stage classification systems
FIG. 2
FIG. 2
AJCC 7th/8th T-stage system, LVI stratification of 7th/8th AJCC T-stage, and proposed T-stage system
FIG. 3
FIG. 3
Lymphovascular invasion
See this image and copyright information in PMC

Comment in

References

    1. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–78. 10.1007/s00268-005-0329-x. - DOI - PubMed
    1. Ayala-Ramirez M, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–99. 10.1530/EJE-13-0519. - DOI - PMC - PubMed
    1. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26. - PubMed
    1. Postlewait LM et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2015. 10.1016/j.jamcollsurg.2015.12.013. - DOI - PMC - PubMed
    1. Bilimoria KY, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6. 10.1002/cncr.23886. - DOI - PubMed

MeSH terms

LinkOut - more resources